These contradictory results about circulating myonectin in patients with metabolic disorders may arise due to technical and biological factors, such as the different criteria for patient selection and influence of covariates (e.g., age, level of physical activity, IR, body composition, and geographic region). This evidence concerns the gene ERFE and metabolic disease.